Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

VG161

Generic Name: VG161

Drug Type: Biotech

Overview

VG161 is an oncolytic virus therapy under investigation for the treatment of cholangiocarcinoma.

Background

VG161 is an oncolytic virus therapy under investigation for the treatment of cholangiocarcinoma.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Phase 2

Recruiting

Posted: 2022/02/04

Sponsor:Virogin Biotech Cana...

ID:NCT05223816

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Breakthrough Chinese Cancer Therapy Uses Modified Viruses to Transform Tumors into 'Foreign Tissue'

2 months ago

Chinese researchers have developed a revolutionary cancer treatment using genetically modified viruses that disguise tumors as foreign pig tissue, triggering powerful immune rejection responses with 90% efficacy in advanced cancer patients.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy